Journal of Applied Physiology Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Appl Physiol 97: 1188-1194, 2004. First published May 7, 2004; doi:10.1152/japplphysiol.00840.2003
8750-7587/04 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
97/4/1188    most recent
00840.2003v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Attalah, H. L.
Right arrow Articles by Delclaux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Attalah, H. L.
Right arrow Articles by Delclaux, C.

Decreased exhaled nitric oxide as a marker of postinsult immune paralysis

Habiba L. Attalah,1 Stéphanie Honoré,1,2 Saadia Eddahibi,1 Elisabeth Marcos,1 Claude-James Soussy,2 Serge Adnot,1,3 and Christophe Delclaux1,3

1Institut National de la Santé et de la Recherche Medicale U492-Université Paris XII, and 2Service de Bactériologie and 3Service de Physiologie, Hôpital Henri Mondor, AP-HP, 94 010 Créteil, France

Submitted 11 August 2003 ; accepted in final form 6 May 2004


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Nitric oxide (NO) regulates neutrophil migration and alveolar macrophage functions such as cytokine synthesis and bacterial killing, both of which are impaired in immune paralysis associated with critical illness. The aim of this study was to determine whether NO is involved in immune paralysis and whether exhaled NO measurement could help to monitor pulmonary defenses. NO production (protein expression, enzyme activity, end products, and exhaled NO measurements) was assessed in rats after cecal ligation and puncture to induce a mild peritonitis (leading to ~20% mortality rate). An early and sustained decrease in exhaled NO was found after peritonitis (from 1 to 72 h) compared with healthy rats [median (25th–75th percentile), 1.5 parts per billion (ppb) (1.2–1.7) vs. 4.0 ppb (3.6–4.3), P < 0.05], despite increased NO synthase-2 and unchanged NO synthase-3 protein expression in lung tissue. NO synthase-2 activity was decreased in lung tissue. Nitrites and nitrates in supernatants of isolated alveolar macrophages decreased after peritonitis compared with healthy rats, and an inhibitory experiment suggested arginase overactivity in alveolar macrophages bypassing the NO substrate. Administration of the NO synthase-2 inhibitor aminoguanidine to healthy animals reproduced the decreased neutrophil migration toward alveolar spaces that was observed after peritonitis, but L-arginine administration after peritonitis failed to correct the defect of neutrophil emigration despite increasing exhaled NO compared with D-arginine administration [4.8 (3.9–5.7) vs. 1.6 (1.3–1.7) ppb, respectively, P < 0.05]. In conclusion, the decrease in exhaled NO observed after mild peritonitis could serve as a marker for lung immunodepression.

cecal ligation and puncture; alveolar macrophage; nitric oxide synthase; arginase


ALTERATIONS IN IMMUNE DEFENSES associated with critical illness, although long described, have only recently been individualized by the term "immune paralysis" (25). Immune paralysis includes functional impairments of monocytes and macrophages and neutrophils (11, 30), the two major phagocytic cells contributing to innate immune defenses. This suggests that immune paralysis may be a major risk factor for nosocomial infections. In keeping with this possibility, we previously described an association between impaired intracellular killing of Staphylococcus aureus by neutrophils and subsequent nosocomial infection (30).

Nitric oxide (NO) regulates neutrophil migration and alveolar macrophage functions such as cytokine synthesis and bacterial killing (15, 36, 19, 34, 23), which are impaired in critically ill patients. One may hypothesize that lung NO production could be affected in these patients because pneumonia is the most common nosocomial infection. Along this line, L-arginine, which is a semiessential amino acid, is the substrate for NO synthesis, and arginine blood concentration is often decreased in critically ill patients (3), a fact that could explain the beneficial effect of formulas with high arginine content in terms of reduction of infectious complications (16).

The respiratory tract is accessible by noninvasive investigation, because NO is present and can be measured in exhaled gas (10). Few studies have evaluated the concentration of exhaled NO in ventilated critically ill patients, and they have shown a decrease in exhaled NO after surgery (18, 9). It could be hypothesized that this unexpected decrease (inasmuch as proinflammatory mediators are known to upregulate inducible NO synthase) in exhaled NO could be a marker of immune paralysis in critically ill patients.

To this end, we used a rat model of peritonitis, in which we measured pulmonary NO production and evaluated potential effects of NO on inflammatory cell phenotype modifications, i.e., abnormal neutrophil migration and alveolar macrophage cytokine synthesis, which are components of immune paralysis.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Animals

Adult male Sprague-Dawley rats (IFFA CREDO Laboratories, L'Arbresle, France) weighing 225–250 g were used in all experiments. The rats were housed in air-filtered, temperature-controlled units and were allowed free access to food and water. The animals were housed as recommended by the European Convention for the Protection of Experimental Animals (Decree no. 2001-131, February 6, 2001). Our local animal subcommittee approved the animal protocols.

Animal Model of Peritonitis

Sepsis was produced in the rats by cecal ligation and puncture (CLP), as described elsewhere (2). After halothane anesthesia, a 3-cm midline abdominal incision was made to expose the cecum, which was ligated with 3-0 silk (Ethicon) suture, just distal to the ileocecal valve to avoid intestinal obstruction. The cecum was punctured twice with a 19-gauge needle. The cecum was then replaced in the peritoneal cavity, and the incision was closed with a continuous 3-0 silk suture. The control (sham-operated) rats underwent the same procedures except that the cecum was neither ligated nor punctured. All rats were given 1 ml of physiological saline subcutaneously for fluid resuscitation during the postoperative period. By using this low number of punctures, a mild localized sepsis was obtained as previously described (2), given a low spontaneous mortality rate (~20%). This design was chosen inasmuch as we previously showed that a postaggressive inhibition of neutrophil migration occurs in this setting that further allows studying almost all rats.

At designated time points after CLP (1, 4, 24, 48, and 72 h), the rats were anesthetized by intraperitoneal injection of pentobarbital, and tracheotomy was performed for mechanical ventilation with a rodent ventilator (tidal volume of 7 ml/kg; respiratory rate of 60/min).

Measurement of Exhaled NO Concentration

Exhaled NO was measured with a chemiluminescence analyzer (EVA 4000, Sérès, Aix en Provence, France), with a lower limit of detection of 1 part per billion (ppb) and a NO sampling rate of 30 l/h. Calibration was performed with a zero gas and standard 100 and 800 ppb NO gas (AGA).

All rats were ventilated with NO-free air. Exhaled breath from each rat was collected in a 6-liter polyethylene bag that did not react with NO. The bag was placed at the expiratory outlet of the ventilator and was connected rapidly to the NO analyzer when filled. Each gas collection lasted ~15 min. Therefore, measurements reported for each time point represent the mean NO concentration in exhaled gas collected over the preceding 15 min. NO concentrations were expressed in ppb.

Plasma Collection

After exhaled gas collection, rats were killed by exsanguination. Blood was obtained, and plasma was separated and stored at –80°C.

Wet-to-Dry Weight Ratio

One lobe of the freshly harvested left lung was separated, weighed, dried at 40°C for 72 h, and weighed again. The wet-to-dry lung weight ratio was calculated by dividing the initial weight by the dry weight. The remaining lobe was frozen in liquid nitrogen and stored at –80°C until use.

Bronchoalveolar Lavage

Bronchoalveolar lavage (BAL) was performed as previously described (2). The left bronchus was clamped for BAL of the right lung by using the tracheotomy tube. Five 4-ml aliquots of 37°C, sterile, pyrogen-free, 0.9% saline were flushed through the tracheotomy tube. The five fractions were recovered and pooled. The total number of cells was counted using a standard hemocytometer. The BAL fluid was then centrifuged at 300 g for 7 min. The supernatant was collected and stored at –80°C for further analysis.

Alveolar Macrophage Isolation

After BAL centrifugation, the cell pellet (>97% macrophages) was suspended in DMEM (Life Technologies, Cergy-Pontoise, France) containing antibiotics (100 U/ml penicillin, 100 mg/ml of streptomycin, and 100 mg/ml gentamicin). The cells, at a concentration of 1 x 106/ml, were incubated for 4 h at 37°C in 5% CO2 with and without stimulation by lipopolysaccharide (LPS, Escherichia coli endotoxin 055:B5 Sigma, 1 µg/ml). Cell supernatants were collected and stored at –80°C for further analysis.

Measurement of NO End Products (Nitrite/Nitrate)

NO is unstable in the presence of oxygen and is rapidly converted into NO2 and NO3 (NO end products: NOx) in liquid media. For measurements of NO production in biological samples (plasma, BAL fluid, and alveolar supernatants), both NO2 and NO3 were converted into NO by using the reducing agent vanadium (III) chloride in acidic solution [hydrochloric acid (HCl) 6N] at 90°C (Nitroflux NT system, Sérès), as described elsewhere (37). NO gas was carried into the NO analyzer (EVA 4000 analyzer) with a constant flow of N2 gas and was quantified with reference to sodium nitrite standards. Before plasma NOx measurement, the frozen plasma was thawed and mixed with methanol (1:1 vol/vol) to precipitate the proteins and then centrifuged at 12,000 g for 20 min at 4°C.

Western Blotting of NO Synthase-2 and NO Synthase-3 Proteins

Immunoblotting for NO synthase (NOS)-2 and NOS-3 proteins was performed as described elsewhere (26). The frozen tissues were homogenized on ice by using a Polytron homogenizer (Kinematica, Steinhofhalde, Switzerland) in 0.1 mM PBS (pH 7.4) containing protease inhibitors (1 µm leupeptin, 1 µM pepstatin A). The homogenates were centrifuged at 490 g for 15 min at 4°C. Protein concentrations of the supernatants were measured by the Bradford method (Pierce, Rockford, IL), and supernatants (150 µg of protein loaded per lane) were then examined by SDS-PAGE. The proteins were transferred to nitrocellulose membranes by electroblotting in a transblot Bio-Rad transfer apparatus (Bio-Rad Laboratories, Richmond, CA). The nitrocellulose membranes were soaked in electroblotting buffer (25 mM Tris·HCl, 193 mM glycine, 20% methanol, pH 8.0) for 15 min before being transferred. After protein transfer, which was carried out for 12 h at 4°C, the membrane was blocked with 5% Tween Tris-buffered saline (TBS-T, 0.15 M NaCl, 10 mM Tris·HCl, 0.05% Tween 20, 5% BSA, pH 8.0) for 1 h at room temperature. The membranes were incubated with primary antibody, the endothelial NOS-3 protein (Transduction Laboratories, Lexington, KY) or the inducible NOS-2 protein (Transduction Laboratories) 1:1,000 for 1 h. The membranes were washed and then incubated with biotinylated IgG secondary antibody (Calbiochem) 1:5,000 for 1 h. The membranes were washed three times in 1% TBS-T. Specific protein was detected by use of horseradish peroxidase (Amersham), and the blots were developed by the Amersham enhanced chemiluminescence detection system. The bands for NOS-2 and/or NOS-3 were visualized and quantified by use of densitometry (personal densitometer SI; Molecular Dynamics).

Measurement of NOS Activity

NOS activity was measured in the lung homogenates on the basis of transformation of L-[H3]arginine to L-[H3]citrulline as described elsewhere (26). The tissue (100 mg) was homogenized on ice with a homogenizer, in four volumes of buffer containing 50 mM Tris·HCl (pH 7.4), 0.1 mM EDTA, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 1 µM leupeptin, 1 µM pepstatin A, and 1 mM PMSF (buffer A). The homogenate was centrifuged at 10,000 g for 30 min at 5°C. The supernatant fraction was used to evaluate NOS-2 activity (cytosolic activity). The pellet (membrane fraction) was resuspended in homogenization buffer containing the detergent CHAPS (20 mM), 1 M KCl, and glycerol (10% vol/vol) and was then allowed to stand on ice for 30 min before centrifugation at 100,000 g for 30 min at 5°C. Activity of NOS-3 in the resultant supernatant fraction (membrane fraction) was determined by measuring Ca2+-dependent conversion of L-[H3]arginine to L-[H3]citrulline. The specific activity of L-[H3]arginine was 320 mCi/mM. The reaction mixture contained the supernatant (<10% in volume), 0.2 µCi L-[H3]arginine, 50 µM L-arginine, 100 µM NADPH, 25 µM tetrahydrobiopterin, 2 µM FAD, and 2 µM flavin mononucleotide. This mixture was incubated for 45 min at 37°C under a calcium-dependent condition, with 0.6 mM Ca2+, corresponding mainly to NOS-3 activity. After the reaction was stopped by the addition of 0.5 M perchloric acid, L-[H3]citrulline and L-[H3]arginine were separated on a cationic ion-exchange column (Shim-pack ISC-05/S0504; Bio-Rad) in a HPLC system (Waters Associates, Milford, MA). The citrulline fraction was collected by a fraction collector (model 201; Gilson, Villiers-le-Bel, France). After addition of a scintillation cocktail, the isotope was counted for 3 min. Specific transformation of L-[H3]citrulline was calculated as follows: the isotope counts at the citrulline fraction eluted from the column of the incubation mixture with the enzymes were subtracted from the isotope counts eluted from the incubation without enzymes, and the remaining counts were then divided by the specific activity (320 mCi/mM). Next, the specific activity of NOS was expressed as picomoles of citrulline formation per milligram protein per 45 min.

Arginase Inhibition Assay

In macrophages, NOSs and arginases compete for the same substrate, L-arginine, to produce NO and urea, respectively (6). Because L-arginine availability is a major determinant for NO synthesis in activated macrophages, we hypothesized that arginase might reduce NO production. To test this hypothesis, we investigated the effect of the specific arginase inhibitor N-hydroxy-nor-L-arginine, diacetate salt [NOHA (33)] (Calbiochem) on NO production. Isolated alveolar macrophages from both CLP rats and healthy control rats were suspended in presence of endotoxin stimulation (LPS, 1.0 µg/ml) for 4 h in the presence or absence of 10 or 100 µM NOHA. NOx concentrations in cell supernatants were measured as described previously.

Macrophage Inflammatory Protein-2 Concentration Measurement in Isolated Alveolar Macrophage Supernatant

Macrophage inflammatory protein-2 (MIP-2) was assayed by use of a specific rat ELISA kit as recommended by the manufacturer (BioSource). The detection limit was 1 pg/ml.

Alveolar Instillation of Endotoxin

As a functional parameter characterizing immune paralysis, neutrophil influx into the lungs was assessed by endotoxin instillation, as previously described (20). Briefly, the rats were anesthetized by halothane administration, the trachea was exposed, and 0.5 ml/kg body wt of LPS (200 µg/kg) dissolved in sterile physiological saline was instilled via a 25-gauge needle. The skin incision was closed with surgical staples, and the rats were allowed to awaken. Four hours later, the rats were anesthetized by intraperitoneal pentobarbital administration to allow biological sample collection, as described previously.

Treatment with the NOS Inhibitor Aminoguanidine

Healthy rats were injected subcutaneously with aminoguanidine (30 mg/kg), and 4 h later exhaled NO was measured to verify NO inhibition. In a separate set of experiments, 4 h after aminoguanidine injection, the rats were instilled with endotoxin (see above) and then killed 4 h later for BAL to assess whether in vivo NO inhibition was associated with modifications in alveolar neutrophil influx.

L-Arginine Administration at the Time of Peritonitis

Rats undergoing peritonitis were treated with either D-arginine (control condition) or L-arginine (both supplied by Sigma, Lille, France) at the end of surgical procedure for 23 h according to the experimental design that has been previously used by Horton and colleagues (17a)., namely 300 mg/kg L- or D-arginine (intraperitoneal administration) at 30 min, 6 h, and 23 h after CLP. In a first set of experiment (D-arginine, n = 3; L-arginine, n = 5), rats were killed at the 24th hour after CLP to measure exhaled NO. In a second set of experiments (D-arginine, n = 3; L-arginine, n = 5), rats underwent endotoxin instillation at the 24th hour after CLP (as described above) and were killed 4 h later to assess neutrophil influx into BAL fluid (as described above). This additional experiment was conducted to evaluate whether L-arginine administration was able to restore NO synthesis (on the basis of exhaled NO measurement) and correct the inability of neutrophils to migrate into alveolar space in response to endotoxin instillation.

Statistical Analysis

All data are expressed as medians (25th–75th percentiles). Data were analyzed with Statview 5.0 (SAS Institute, Berkeley, NC). For between-group comparisons of continuous variables, we used the Mann-Whitney U-test or the Kruskal-Wallis test, as appropriate. Statistical significance was defined as P < 0.05.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Decreased Exhaled NO After Peritonitis

Experiments were designed to describe the time course of NO exhalation after mild peritonitis or a sham operation. The results are summarized in Table 1. An early decrease in exhaled NO was found after mild peritonitis that seemed related to a decrease in NO production, because NO-derived end products were not increased in BAL fluid or plasma. Furthermore, in addition to this decrease in NO production by the lungs, we found a decrease in NO production by isolated alveolar macrophages, which paralleled the decrease in exhaled NO (Table 1 and Fig. 1). By contrast, sham-operated animals exhibited a trend toward an early decrease in exhaled NO (4th hour), which was subsequently followed by a rapid increase in NO synthesis (24th hour).


View this table:
[in this window]
[in a new window]
 
Table 1. Time course of exhaled NO and NOx levels in BAL, alveolar macrophages, and plasma after CLP or sham surgery in rats, as compared with healthy rats

 


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1. Time course of exhaled nitric oxide (NO) and nitrites or nitrates in supernatants of unstimulated alveolar macrophages. This figure illustrates the parallel course of exhaled NO [parts per billion (ppb)] and ex vivo production of nitrites and nitrates by isolated alveolar macrophages (µM) in healthy animals (horizontal dashed lines), sham-operated animals, and rats with peritonitis via cecal ligation and puncture (CLP). For statistical comparison and percentile ranges, see Table 1.

 
Mechanisms of Decreased Lung NO Synthesis

NOS assays on lung homogenates.   The decrease in NO output was not related to downregulation of type 2 or 3 NOS proteins, as shown by the Western blot assays on lung homogenates. Expression of NOS-3 was not significantly increased after CLP, whereas expression of NOS-2 was significantly increased (Fig. 2). We then assessed NOS activities and found a decrease in NOS-2 activity in lung homogenates of CLP rats compared with healthy rats (Fig. 3).



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 2. Time course of NO synthase (NOS)-2 and NOS-3 protein expression in the lungs, as assessed by immunoblotting. A, top: inducible NOS-2 expression (arrow shows the 130-kDa NOS-2 protein band). Shown is a representative (of 5 experiments) Western blotting analyses of lung homogenates obtained from rats at different time points after CLP to induce peritonitis, compared with healthy rats (lane LPS–) and a positive control [lane LPS+: healthy rat instilled intratracheally with lipopolysaccharide (LPS) and killed 4 h later]. In healthy rats, NOS-2 protein is almost undetectable and peritonitis induces NOS-2 protein, which is clearly evident from the 48th hour, as demonstrated elsewhere (27). A, bottom: endothelial NOS expression (arrow shows the 140-kDa NOS-3 protein band). Shown is a representative Western blotting analysis of lung homogenates obtained from rats at different time points after CLP to induce peritonitis, after aminoguanidine administration to a healthy rat (lane amino, see MATERIALS AND METHODS), after LPS instillation in a healthy rat (lane LPS+: healthy rat instilled intratracheally with LPS and killed 4 h later), and in a noninstilled healthy rat (lane LPS–). No significant modifications in endothelial NOS protein expression were evidenced except in the healthy rat given the NOS-2 inhibitor (aminoguanidine), as previously shown (26). B: densitometry analysis and statistical comparisons. Results (arbitrary units) are expressed as percentage of control condition (healthy rats = 100%). *P < 0.05 compared with control condition (dashed line).

 


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3. NOS activity measured in lung homogenates at predefined time points (1, 4, 24, 48, and 72 h) after CLP to induce peritonitis, compared with healthy rats (control, time 0) and sham-operated rats (studied at the 24th hour). NOS activities, in supernatant fraction (cytosol, mainly NOS-2) (A) and membrane fraction (mainly NOS-3) (B), were measured as the enzymatic conversion of L-[H3]arginine to L-[H3]citrulline as described in MATERIALS AND METHODS. The results are expressed in picomoles per milligram per protein per 45-min incubation; n = 4 rats in each group. Results are expressed as median (25th–75th percentiles). *P < 0.05 compared with control condition.

 
Assays on isolated alveolar macrophages.   To further explore the mechanism of decreased NO production by isolated alveolar macrophages, experiments using a specific arginase inhibitor (NOHA) were conducted (Table 2). Arginase inhibition caused a dose-dependent increase in NOx levels in alveolar macrophage supernatants of both healthy and CLP rats. Interestingly, arginase inhibition led to significantly greater enhancement of NOx production by macrophages from CLP rats than from healthy rats, suggesting enhanced NOS activity in the CLP rats.


View this table:
[in this window]
[in a new window]
 
Table 2. Experiments on isolated alveolar macrophages

 
Effects of Decreased Lung NO Production on Immune Function Regulation

In these experiments, we evaluated whether the decrease in NO production associated with mild CLP was involved in the inhibition of alveolar neutrophil migration that occurs after injury. After LPS instillation 24 or 72 h after CLP, the neutrophil influx into the alveolar spaces was less marked than in healthy rats. In vivo inhibition of NO synthesis by treatment of healthy rats with aminoguanidine led to a significant decrease in both exhaled NO [1.7 ppb (1.2–2.4), n = 3] and NOx in supernatants of isolated alveolar macrophages [unstimulated condition, 0.4 µM (0.2–0.7)] compared with healthy rats. Furthermore, aminoguanidine administration was associated with inhibition of neutrophil migration toward the alveolar spaces after LPS administration (Fig. 4).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 4. Alveolar cell recruitment after endotoxin instillation in rats with peritonitis induced by CLP, compared with healthy rats treated by aminoguanidine (amino) or with healthy rats. Alveolar cell recruitment was assessed 4 h after endotoxin (LPS) instillation by bronchoalveolar lavage (BAL). Differential cell counts demonstrated that almost all recruited cells were neutrophils (>95% of total cells in LPS-instilled conditions). In healthy rats without LPS instillation, alveolar macrophages were the predominant cell type (>97%). Results are expressed as median (25th–75th percentiles). *P < 0.05 compared with healthy plus LPS condition. Median (25th–75th percentiles) exhaled NO concentration in each group: healthy plus LPS, 23.9 ppb (15.2–32.1); CLP-24 h plus LPS, 13.5 ppb (7.2–16.5); CLP-72 h plus LPS, 13.3 ppb (6.2–15.9); healthy plus LPS and aminoguanidine, 35.1 ppb (19.2–43.4).

 
To further explain the role of NO in macrophage functions, we assessed MIP-2 synthesis by isolated alveolar macrophages. MIP-2 is a chemokine involved in recruiting neutrophils to the alveolar spaces (Fig. 5). An increased MIP-2 secretion by isolated alveolar macrophages was evidenced in both the sham-operated and the CLP rats, despite the absence of alveolar neutrophil influx (data not shown). In vivo (aminoguanidine) inhibition of NO synthesis in healthy rats was followed by increased MIP-2 production into supernatants of isolated alveolar macrophages.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5. Macrophage inflammatory protein-2 (MIP-2) concentration in isolated alveolar macrophage supernatants. MIP-2 concentrations were measured in supernatants of isolated alveolar macrophages (4-h incubation) by ELISA (see MATERIALS AND METHODS). MIP-2 concentrations increased after both surgeries, i.e., sham surgery or CLP, and after treatment of healthy rats with an inducible NOS-2 inhibitor [aminoguanidine (amino)]. Results are expressed as median (25th–75th percentiles). *P < 0.05 compared with healthy condition.

 
Effect of L-Arginine Supplementation

Administration of L-arginine was associated with an increase in exhaled NO compared with D-arginine administration [4.8 (3.9–5.7) vs. 1.6 (1.3–1.7) ppb, respectively, P < 0.05]; however, despite increased NO production, alveolar neutrophil recruitment 4 h after endotoxin instillation was unmodified [L-arginine: 86 (69–122), 104 cells/ml vs. D-arginine: 75 (64–110), 104 cells/ml BAL fluid; P = NS]. In an additional experiment, rats supplemented with either L-arginine or D-arginine (n = 4 per group) were killed 24 h after endotoxin instillation to assess whether the kinetic of alveolar neutrophil recruitment was modified by L-arginine administration. A similar number of alveolar neutrophil was demonstrated whatever the treatment [L-arginine: 426 (369–493), 104 cells/ml vs. D-arginine: 387 (276–456), 104 cells/ml BAL fluid; P = NS].


    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
Increased levels of exhaled NO have been found during lung infections, as well as during intravenous endotoxin administration (1, 14). The contribution of alveolar macrophages to pulmonary NO production after endotoxin injection has been demonstrated by Fujii and colleagues (14). Unexpectedly, in our model of mild peritonitis, we found no increase in exhaled NO, but on the contrary, exhaled NO concentration was decreased after peritonitis. In keeping with our finding, a significant decrease in exhaled NO has been found in patients after cardiopulmonary bypass (18). Interestingly, L-arginine administration in this latter setting has been found to decrease the occurrence of infectious complications (16). The beneficial effects of immunonutrition using formulas with high content of L-arginine may be attributed to decreased blood concentration of L-arginine, which is a semiessential amino acid (3). We found no increase in NO end products in plasma or BAL fluid, although NOS-2 protein was upregulated and NOS-3 protein unchanged. The decrease in lung NOS-2 activity and exhaled NO further suggests that NO production was decreased in our model.

There is controversy in the literature over whether NO released during the inflammatory process favors or inhibits neutrophil migration. However, exposure of neutrophils to exogenous NO induces a rapid and persistent morphological hyperpolarization followed by migrational arrest due to reduction of the F-actin content (22). Moreover, NO supplied exogenously into reactions containing activated endothelium downregulates proinflammatory activity, such as the secretion of chemokines, and functional activity, such as transendothelial migration of neutrophils (13). These in vitro experiments may explain that the inhibition of neutrophil migration by NO is due to inhibition of a neutrophil-endothelium adhesion mechanism. In vivo experiments further support the role of NO in the inhibition of neutrophil migration at the time of severe sepsis (4) or subsequent to sepsis (for instance after intravenous endotoxin injection; Ref. 32). These effects of NO have previously been demonstrated to be mediated via inducible NOS-2 activity (29). Eventually, inhaled NO has also been demonstrated to reduce neutrophil emigration in some studies (15) (however, we found an opposite response in a bacterial pneumonia model; Ref. 19). Consequently, we were surprised to find an inhibition of neutrophil migration toward alveolar spaces after a mild peritonitis that was not associated with increased NO synthesis (at least in the pulmonary compartment from the first hour of injury). Furthermore, we have previously shown using the same animal model an increase in blood proinflammatory cytokines (2), which have been shown to inhibit subsequent neutrophil emigration via NO synthesis (31). On the other hand, in a model of trinitrobenzene sulfonic acid-induced colitis in rats, nitro-L-arginine methyl ester reduced neutrophil influx (17). Therefore, reduced NO synthesis has also been associated with inability for neutrophil to migrate.

A limitation of our study is the fact that sham-operated rats were not studied at all time points. These experiments showed a transient decrease in exhaled NO (4th hour) after sham surgery followed by an unexpected rebound of NO synthesis (24th hour). We did not subsequently performed experiments in sham rats inasmuch as statistical calculations demonstrated that we were unable to demonstrate significant differences between both surgeries using small number of animals (<30 per group). Consequently, from this study we cannot infer whether our results are related to surgical injury and/or septic injury. However, we previously showed that both surgeries were characterized by an increase in plasma IL-10 (2), an anti-inflammatory cytokine involved in immune paralysis (25).

To further explore the decrease in exhaled NO in our rats with mild peritonitis, we conducted experiments on isolated alveolar macrophages, because these cells also showed a decrease in NO synthesis, suggesting a link between cellular and organ impairment of NO production. Several lines of evidence led us to hypothesize that stress, via increased production of catecholamines and their cellular effects mediated by cAMP, leads to arginase upregulation and decreased arginine availability for NOS, the end result being impaired NO production (5, 8, 28). We chose to explore this hypothesis in isolated alveolar macrophages because arginase regulation in these cells has been extensively described (7, 24, 33). In macrophages, L-arginine can be used by NOSs and arginases to form NO and urea, respectively. A similar balance between arginases and NOS exists in endothelial cells (21, 38). Thus activation of arginases may be an effective mechanism for regulating NO production through substrate competition. Support for this possibility was provided by our experiments showing an increase in NOx production in the presence of a specific arginase inhibitor. The results of these ex vivo experiments are in agreement with in vitro evidence that there is impairment in NO production by macrophages or endothelial cells when both NOS-2 and arginase are induced by endotoxin (7, 21).

Although the reason for the decrease in lung NO production remains speculative, besides a decrease in substrate availability either relative (competition) or absolute (deficiency), several proteins have been shown to block the dimerization and activity of NOS isoforms (6). Furthermore, NOS-2 enzyme activity has been shown to be dependent on molecular oxygen levels (12); conceivably, a decrease in partial pressure of oxygen due to lung edema could also have reduced NO synthesis. The decrease in neutrophil emigration was not clearly related to defective substrate availability because L-arginine administration failed to improve neutrophil migration despite restoring exhaled NO concentration.

Inhibition of NOS-2 activity by treatment of healthy rats with aminoguanidine, which reduced both exhaled NO and NOx production by alveolar macrophages, reproduced the impairment of neutrophil migration to alveolar spaces. The impairment in neutrophil migration was not related to a decrease in MIP-2 secretion by alveolar macrophages, because MIP-2 secretion was stimulated after both CLP and aminoguanidine administration. This last finding may be ascribable to decreased NO production by alveolar macrophages because NO is known to inhibit nuclear factor-{kappa}B (via nitrosylation), a transcription factor responsible for proinflammatory cytokine upregulation (34). Given the lack of selectivity of the high dose of aminoguanidine administered, it is also conceivable that the inhibitor may have inhibited endothelial NOS-3 remote from the inflammatory locus, resulting in vasoconstriction, reduced blood flow delivery, and reduced neutrophil emigration toward alveolar spaces.

We previously showed that peritonitis was characterized by an increase in plasma IL-10 (2), a major anti-inflammatory cytokine involved in immune paralysis (25) and macrophage arginase upregulation (24). Interestingly, Tsuei and colleagues (35) have demonstrated an increased arginase expression in blood monocytes that may have contributed to postsurgical immune dysfunction, which may have been regulated via plasma IL-10 secretion. These results suggest that plasma IL-10 and exhaled NO may be markers for immune paralysis. NO exhalation measurement has the advantage of being noninvasive. Clinical studies are ongoing in our institution to determine whether the decrease in exhaled NO is related to the alveolar or to the bronchial compartment, both of which contribute to exhaled NO (10), and whether exhaled NO may be a prognosis factor in critically ill patients.

In summary, mild peritonitis (local infection) is associated with an early decrease in exhaled NO that is related to decreased lung production. This impaired NO production is associated with impaired neutrophil migration into the alveolar spaces that may contribute to immune paralysis in critically ill patients. Thus exhaled NO may represent a noninvasive marker for immune paralysis.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
This study has been supported by a grant from "Legs Poix."


    ACKNOWLEDGMENTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 
The authors thank Dr. Antoinette Wolfe for expert manuscript review (and English corrections).


    FOOTNOTES
 

Address for reprint requests and other correspondence: C. Delclaux, Service de Physiologie-Explorations Fonctionnelles, Hôpital Henri Mondor, 51 Ave. du Maréchal de Lattre de Tassigny, 94 010 Créteil, France (E-mail: christophe.delclaux{at}creteil.inserm.fr).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 ACKNOWLEDGMENTS
 REFERENCES
 

  1. Aaron SD, Valenza F, Volgyesi G, Mullen JB, Slutsky AS, and Stewart TE. Inhibition of exhaled nitric oxide production during sepsis does not prevent lung inflammation. Crit Care Med 26: 309–314, 1998.[CrossRef][Web of Science][Medline]
  2. Attalah HL, Azoulay E, Yang K, Lasclos C, Jouault H, Soussy CJ, Guillot T, Brochard L, Brun-Buisson C, Harf A, and Delclaux C. Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit Care Med 30: 2107–2114, 2002.[CrossRef][Web of Science][Medline]
  3. Bansal V and Ochoa JB. Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care 6: 223–228, 2003.[CrossRef][Web of Science][Medline]
  4. Benjamim CF, Ferreira SH, and Cunha FQ. Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 182: 214–223, 2000.[CrossRef][Web of Science][Medline]
  5. Bernard AC, Fitzpatrick EA, Maley ME, Gellin GL, Tsuei BJ, Arden WA, Boulanger BR, Kearney PA, and Ochoa JB. Beta adrenoceptor regulation of macrophage arginase activity. Surgery 127: 412–418, 2000.[CrossRef][Web of Science][Medline]
  6. Bogdan C. Nitric oxide and the immune response. Nat Immun 2: 907–916, 2001.
  7. Chang CI, Liao JC, and Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol Heart Circ Physiol 274: H342–H348, 1998.[Abstract/Free Full Text]
  8. Collins JL, Vodovotz Y, Yoneyama T, Hatakeyama K, Green AM, and Billiar TR. Catecholamines decrease nitric oxide production by cytokine-stimulated hepatocytes. Surgery 130: 256–264, 2001.[CrossRef][Web of Science][Medline]
  9. Cuthbertson BH, Stott SA, and Webster NR. Exhaled nitric oxide as a marker of lung injury in coronary artery bypass surgery. Br J Anaesth 89: 247–250, 2002.[Abstract/Free Full Text]
  10. Delclaux C, Mahut B, Zerah-Lancner F, Delacourt C, Laoud S, Cherqui D, Duvoux C, Mallat A, and Harf A. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med 165: 332–337, 2002.[Abstract/Free Full Text]
  11. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, and Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3: 678–681, 1997.[CrossRef][Web of Science][Medline]
  12. Dweik RA, Laskowski D, Abu-Soud HM, Kaneko F, Hutte R, Stuehr DJ, and Erzurum SC. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. J Clin Invest 101: 660–666, 1998.[Web of Science][Medline]
  13. Fowler AA III, Fisher BJ, Sweeney LB, Wallace TJ, Natarajan R, Ghosh SS, and Ghosh S. Nitric oxide regulates interleukin-8 gene expression in activated endothelium by inhibiting NF-kappaB binding to DNA: effects on endothelial function. Biochem Cell Biol 77: 201–208, 1999.[CrossRef][Web of Science][Medline]
  14. Fujii Y, Goldberg P, and Hussain SN. Contribution of macrophages to pulmonary nitric oxide production in septic shock. Am J Respir Crit Care Med 157: 1645–1651, 1998.[Medline]
  15. Guidot DM, Hybertson BM, Kitlowski RP, and Repine JE. Inhaled NO prevents IL-1-induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am J Physiol Lung Cell Mol Physiol 271: L225–L229, 1996.[Abstract/Free Full Text]
  16. Heyland DK, Novak F, Drover JW, Jain M, Su X, and Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 286: 944–953, 2001.[Abstract/Free Full Text]
  17. Hogaboam CM, Jacobson K, Collins SM, and Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol Gastrointest Liver Physiol 268: G673–G684, 1995.[Abstract/Free Full Text]
  18. Horton JW, White J, Maass D, and Sanders B. Arginine in burn injury improves cardiac performance and prevents bacterial translocation. J Appl Physiol 84: 695–702, 1998.[Abstract/Free Full Text]
  19. Ishibe Y, Liu R, Hirosawa J, Kawamura K, Yamasaki K, and Saito N. Exhaled nitric oxide level decreases after cardiopulmonary bypass in adult patients. Crit Care Med 28: 3823–3827, 2000.[CrossRef][Web of Science][Medline]
  20. Jean D, Maitre B, Tankovic J, Meignan M, Adnot S, Brun-Buisson C, Harf A, and Delclaux C. Beneficial effects of nitric oxide inhalation on pulmonary bacterial clearance. Crit Care Med 30: 442–447, 2002.[CrossRef][Web of Science][Medline]
  21. Jean D, Rezaiguia-Delclaux S, Delacourt C, Leclercq R, Lafuma C, Brun-Buisson C, Harf A, and Delclaux C. Protective effect of endotoxin instillation on subsequent bacteria-induced acute lung injury in rats. Am J Respir Crit Care Med 158: 1702–1708, 1998.[Abstract/Free Full Text]
  22. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, and Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 280: E75–E82, 2001.[Abstract/Free Full Text]
  23. Loitto VM, Nilsson H, Sundqvist T, and Magnusson KE. Nitric oxide induces dose-dependent Ca2+ transients and causes temporal morphological hyperpolarization in human neutrophils. J Cell Physiol 182: 402–413, 2000.[CrossRef][Web of Science][Medline]
  24. Marshall HE and Stamler JS. Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB. Am J Respir Cell Mol Biol 21: 296–297, 1999.[Free Full Text]
  25. Morris SM Jr, Kepka-Lenhart D, and Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol Endocrinol Metab 275: E740–E747, 1998.[Abstract/Free Full Text]
  26. Munford RS and Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163: 316–321, 2001.[Free Full Text]
  27. Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, Zerbib E, Dulmet E, Moreau R, Dinh-Xuan AT, Simonneau G, and Herve P. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 164: 879–885, 2001.[Abstract/Free Full Text]
  28. Okamoto I, Abe M, Shibata K, Shimizu N, Sakata N, Katsuragi T, and Tanaka K. Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. Am J Respir Crit Care Med 162: 716–722, 2000.[Abstract/Free Full Text]
  29. Rodriguez-Galan MC, Sotomayor C, Costamagna ME, Cabanillas AM, Renteria BS, Masini-Repiso AM, and Correa S. Immunocompetence of macrophages in rats exposed to Candida albicans infection and stress. Am J Physiol Cell Physiol 284: C111–C118, 2003.[Abstract/Free Full Text]
  30. Secco DD, Paron JA, de Oliveira SH, Ferreira SH, Silva JS, and Cunha Fde Q. Neutrophil migration in inflammation: nitric oxide inhibits rolling, adhesion and induces apoptosis. Nitric Oxide 9: 153–164, 2003.[CrossRef][Web of Science][Medline]
  31. Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, and Delclaux C. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30: 315–322, 2002.[CrossRef][Web of Science][Medline]
  32. Tavares-Murta BM, Cunha FQ, and Ferreira SH. The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide production. Br J Pharmacol 124: 1369–1374, 1998.[CrossRef][Web of Science][Medline]
  33. Tavares-Murta BM, Machado JS, Ferreira SH, and Cunha FQ. Nitric oxide mediates the inhibition of neutrophil migration induced by systemic administration of LPS. Inflammation 25: 247–253, 2001.[CrossRef][Web of Science][Medline]
  34. Tenu JP, Lepoivre M, Moali C, Brollo M, Mansuy D, and Boucher JL. Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide 3: 427–438, 1999.[CrossRef][Web of Science][Medline]
  35. Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, and Kavuru MS. Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol 17: 279–283, 1997.[Abstract/Free Full Text]
  36. Tsuei BJ, Bernard AC, Shane MD, Shirley LA, Maley ME, Boulanger BR, Kearney PA, and Ochoa JB. Surgery induces human mononuclear cell arginase I expression. J Trauma 51: 497–502, 2001.[Web of Science][Medline]
  37. VanUffelen BE, de Koster BM, Van den Broek PJ, VanSteveninck J, and Elferink JG. Modulation of neutrophil migration by exogenous gaseous nitric oxide. J Leukoc Biol 60: 94–100, 1996.[Abstract]
  38. Yang F, Troncy E, Francoeur M, Vinet B, Vinay P, Czaika G, and Blaise G. Effects of reducing reagents and temperature on conversion of nitrite and nitrate to nitric oxide and detection of NO by chemiluminescence. Clin Chem 43: 657–662, 1997.[Abstract/Free Full Text]
  39. Zhang C, Hein TW, Wang W, Chang CI, and Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 15: 1264–1266, 2001.[Free Full Text]



This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J.-M. Tadie, P. Henno, I. Leroy, C. Danel, E. Naline, C. Faisy, M. Riquet, M. Levy, D. Israel-Biet, and C. Delclaux
Role of nitric oxide synthase/arginase balance in bronchial reactivity in patients with chronic obstructive pulmonary disease
Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L489 - L497.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
97/4/1188    most recent
00840.2003v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Attalah, H. L.
Right arrow Articles by Delclaux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Attalah, H. L.
Right arrow Articles by Delclaux, C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.